Consultant-Needed-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SCO-101,Taxane

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Innovation Fund Denmark

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Funding February 19, 2020

            Details:

            The grant of DKK 5 million from Innovation Fund Denmark is earmarked for the clinical phase II development of SCO-101 in metastatic pancreatic cancer.